Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transcriptomic Signatures of Fluad vs Fluzone High-Dose
NCT03603509Phase 4Completed
- Sponsor
- Mayo Clinic
- Start
- Aug 2018
- Primary completion
- Jan 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Fluzone Trivalent and influenza virus vaccine, split virion in influenza (2 arms), sponsored by Mayo Clinic. Primary endpoints: Innate Cell IFNa2a Production at Day 1, Hemagglutination Inhibition Antibody Titer at Day 28 and 5 more. Started Aug 2018; status: completed.
02
Drugs
Fluzone Trivalentinfluenza virus vaccine, split virion
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03603509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603509.